The effect of Mycobacterium tuberculosis treatment on thrombelastography-assessed haemostasis: a prospective cohort study

Hans Johan Niklas Lorentsson*, Christina R. Clausen, Daniel Faurholt-Jepsen, Katrine Bagge Hansen, Sidse Graff Jensen, Rikke Krogh-Madsen, Per G. Hagelqvist, Pär I. Johansson, Tina Vilsbøll, Filip K. Knop, Pernille Ravn

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

7 Downloads (Pure)

Abstract

Background and objective: Tuberculosis disease (TB) and tuberculosis infection (TBI) have been associated with increased risk of cardiovascular disease which may be connected to infection-related haemostatic changes. It is unknown if treatment of Mycobacterium tuberculosis influences haemostasis. Here, we assessed if TB or TBI treatment affects thrombelastography (TEG)-assessed haemostasis. Methods: Individuals with TB or TBI were included from a TB outpatient clinic in Copenhagen, Denmark. Patients treated with antithrombotic medication or systemic immunosuppressants were excluded. TEG analysis was performed before and after TB/TBI treatment using the TEG®6s analyser to provide data on the reaction time of clot initiation (R) (min), the speed of clot formation (K) (min) and clot build-up (Angle) (°), maximum clot strength (MA) (mm), and clot breakdown/fibrinolysis (LY30) (%). Differences in TEG were assessed using paired t tests. Results: We included eleven individuals with TB with median [interquartile range] [IQR] age 52 (Liu et al. in Medicine (United States) 95, 2016) years and mean (standard deviation) (SD) body mass index (BMI) 24.7 (6.3) kg/m2 as well as 15 individuals with TBI with median [IQR] age 49 (Wells et al. in Am J Respir Crit Care Med 204:583, 2021) years and BMI 26.0 (3.2) kg/m2. Treatment reduced MA for both TB (64.0 (6.3) vs. 57.9 (5.2) mm, p = 0.016) and TBI (61.3 (4.1) vs. 58.6 (5.0) mm, p = 0.023) whereas R, K, Angle and LY30 were unaffected. Conclusion: TEG analysis showed that treatments of TB and TBI were associated with reduced MA which may indicate the existence of cardiovascular benefits from therapy. Trial registration: Registered at ClinicalTrials.gov 05 April 2021 with registration number NCT04830462.

Original languageEnglish
Article number54
JournalThrombosis Journal
Volume22
Issue number1
Number of pages8
ISSN1477-9560
DOIs
Publication statusPublished - 2024

Bibliographical note

Publisher Copyright:
© The Author(s) 2024.

Keywords

  • Cardiovascular disease
  • Inflammation
  • Thrombelastography
  • Tuberculosis disease
  • Tuberculosis infection

Cite this